Recent Updates
Recently added Catalysts
ABUS

Arbutus to Present at 2017 Wedbush PacGrow Healthcare Conference

Key Takeaway: VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and busine

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
2%
average across 5 past catalysts
Cash runway
~46 mo
Minimal dilution risk
Lead asset
TKM-080301
Phase 1 · Cancer

Full Press Release Details

VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the 2017 Wedbush PacGrow Healthcare Conference at 10:55am ET on Wednesday, August 16, 2017, at Le Parker Meridien in New York.
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Last updated: Aug 14, 2017